← Eichor
Study identifier: NCT06794086 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

Condition: Colorectal Cancer · Liver Metastases  ·  Sponsor: Jun Huang

PhasePhase 3
Planned participants24
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing high-level evidence-based medical evidence for the use of SBRT combined with PD-1 inhibitors in the treatment of unresectable colorectal cancer liver metastasis.

This description comes directly from the study's public registry record.

Talk to the study team

Jun Huang, PhD.  ·  13926451242  ·  huangj97@mail.sysu.edu.cn

Fang He, MD.  ·  18826059789  ·  hefang23@mail.sysu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sixth Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06794086